

1 **Title: SARS-CoV-2 Seroepidemiology in Children and Adolescents**

2 Rebecca E Levorson, Erica Christian, Brett Hunter, Jasdeep Sayal, Jiayang Sun, Scott A Bruce,
3 Stephanie Garofalo, Matthew Southerland, Svetlana Ho, Shira Levy, Christopher Defillipi, Lilian
4 Peake, Frederick C Place*, Suchitra K Hourigan*

5 *Authors contributed equally

- 6
- 7 1. Rebecca E Levorson, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church,
8 VA 22042. and Pediatric Specialists of Virginia, 3023 Hamaker Court, Fairfax, VA
9 22031.
 - 10 2. Erica Christian, MS. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA
11 22042
 - 12 3. Brett Hunter, PhD. Department of Statistics, George Mason University. 4400 University
13 Dr, Fairfax, VA 22030
 - 14 4. Jasdeep Sayal, MBA. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA
15 22042
 - 16 5. Jiayang Sun, PhD. Department of Statistics, George Mason University. 4400 University
17 Dr, Fairfax, VA 22030
 - 18 6. Scott A Bruce, PhD. Department of Statistics, George Mason University. 4400 University
19 Dr, Fairfax, VA 22030
 - 20 7. Stephanie Garofalo, RN. Inova Heart and Vascular Institute. 3300 Gallows Rd, Falls
21 Church, VA 22042.
 - 22 8. Matthew Southerland, BS. Inova Heart and Vascular Institute. 3300 Gallows Rd, Falls
23 Church, VA 22042.
 - 24 9. Svetlana Ho, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA 22042
 - 25 10. Shira Levy, MA. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA 22042
 - 26 11. Christopher Defillipi, MD. Inova Heart and Vascular Institute. 3300 Gallows Rd, Falls
27 Church, VA 22042.
 - 28 12. Lilian Peake, MD, MPH. Virginia Department of Health. 109 Governor Street,
29 Richmond, VA 23219.
 - 30 13. Frederick C Place, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church, VA
31 22042
 - 32 14. Suchitra K Hourigan, MD. Inova Children's Hospital. 3300 Gallows Rd, Falls Church,
33 VA 22042 and Pediatric Specialists of Virginia, 3023 Hamaker Court, Fairfax, VA
34 22031..

35

36 **Corresponding author:** Suchitra K Hourigan, MD. Inova Children's Hospital. 3300 Gallows
37 Rd, Falls Church, VA 22042. Email:suchihourigan@gmail.com. Tel: 410-917-3331.

38

39 **Short title:** SARS-CoV-2 Seroepidemiology in Children

40

41

42

43 **Conflict of Interest Disclosures:**

44 Author Christopher Defillipi consults for Ortho Diagnostics, Abbott Diagnostics, and Siemens
45 Healthineers. No other authors have any conflicts of interest relevant to this article to disclose.

46 **Funding/Support and Role of Funder:**

47 The Virginia Department of Health provided funding for this study. The Virginia Department of
48 Health, in conjunction with the authors of this manuscript, were involved in study design, the
49 writing of the report and the decision to submit the paper for publication. The Virginia
50 Department of Health were not involved in collection, analysis or interpretation of the data.
51 Research reported in this publication was also supported in part by the National Institute of Child
52 Health and Human Development under Award Number K23HD099240 (Hourigan). Research
53 reported in this publication was also supported in part via a subcontract from the parent award by
54 the National Center for Advancing Translational Sciences of the National Institutes of Health
55 under Award Number UL1TR003015 (Hunter, Sun, Bruce). The content is solely the
56 responsibility of the authors and does not necessarily represent the official views of the National
57 Institutes of Health.

58

59 **Article Summary:** 8.5% of children had SARS-CoV-2 antibodies in Fall 2020, double the adult
60 rate. The role of pediatric infection is important to consider in mitigation strategies.

61 **What's Known on This Subject:**

62 SARS-CoV-2 pediatric seroepidemiologic data is limited. Reported viral rates underestimate the
63 burden of infection in children due to mild or asymptomatic disease. Limited cohorts of children
64 suggest low seropositivity rates compared to adults.

65 **What This Study Adds:**

66 US children in the largest SARS-CoV-2 seroepidemiology study to date had double the rate of
67 antibodies compared to adults. Most children were asymptomatic. Risk factors include age,
68 ethnicity and living conditions. Most children made antibodies to different antigens of SARS-
69 CoV-2.

70

71

72

73

74

75

76 **Contributor's Statement**

77 Dr Levorson, Dr Place and Dr Hourigan conceptualized and designed the study, enrolled
78 subjects, and/or collected clinical samples and data, drafted the initial manuscript and reviewed
79 and revised the manuscript.

80 Ms Christian, Ms Sayal, Ms Levy and Dr Ho enrolled subjects, and/or collected clinical samples
81 and data and reviewed and revised the manuscript.

82 Dr Hunter, Dr Sun and Dr Bruce conceptualized and designed the study, performed statistical
83 analyses of the data and reviewed and revised the manuscript.

84 Mr Southerland performed and provided oversight of laboratory analyses and reviewed and
85 revised the manuscript.

86 Ms Garofalo, Dr Defillipi and Dr Peake conceptualized and designed the study and reviewed and
87 revised the manuscript.

88 All authors approved the final manuscript as submitted and agree to be accountable for all
89 aspects of the work.

90

91

92

93

94

95

96

97

98

99

100

101 **Abstract**

102 **Objectives:** Pediatric SARS-CoV-2 data remain limited and seropositivity rates in children were
103 reported as <1% early in the pandemic. Seroepidemiologic evaluation of SARS-CoV-2 in
104 children in a major metropolitan region of the United States was performed.

105 **Methods:** Children and adolescents ≤ 19 years were enrolled in a cross-sectional, observational
106 study of SARS-CoV-2 seroprevalence from July-October 2020 in Northern Virginia, United
107 States. Demographic, health, and COVID-19 exposure information was collected, and blood was
108 analyzed for SARS-CoV-2 spike protein total antibody. Risk factors associated with SARS-
109 CoV-2 seropositivity were analyzed. Orthogonal antibody testing was performed, and samples
110 were evaluated for responses to different antigens.

111 **Results:** In 1038 children, the anti-SARS-CoV-2 total antibody positivity rate was 8.5%. After
112 multivariate logistic regression, significant risk factors included Hispanic ethnicity, public or
113 absent insurance, a history of COVID-19 symptoms, exposure to person with COVID-19, a
114 household member positive for SARS-CoV-2 and multi-family or apartment dwelling without a
115 private entrance. 66% of seropositive children had no symptoms of COVID-19. Orthogonal
116 antibody testing with a receptor binding domain specific antigen revealed a high concordance of
117 80.5%. Children also demonstrated a robust immune response to the nucleocapsid antigen.

118 **Conclusions:** A much higher burden of SARS-CoV-2 infection, as determined by seropositivity,
119 was found in children than previously reported; this was also higher compared to adults in the
120 same region at a similar time. Contrary to prior reports, we determined children shoulder a
121 significant burden of COVID-19 infection. The role of children's disease transmission must be
122 considered in COVID-19 mitigation strategies including vaccination.

123

124 Key Words: COVID-19; SARS-CoV-2; serology; antibody; seroprevalence; children; pediatrics

125

126

127

128

129

130

131

132 **Introduction**

133 Current epidemiologic data in the United States (US) and globally indicating sustained community
134 transmission of SARS-CoV-2 is indisputable. The extent of SARS-CoV-2 community transmission
135 remains incompletely understood, particularly regarding children. Initially, our understanding was
136 dependent upon aggregate molecular testing for acute infection and largely missed mild and
137 asymptomatic infections. Based on this data, early reports misleadingly suggested that children were
138 largely spared infection from SARS-CoV-2 [1,2].

139 Seroprevalence estimates can be useful to understand the true cumulative incidence in a given population.
140 Antibody seropositivity provides data about asymptomatic or subclinical infections that would not be
141 detected by surveillance relying on interactions with the health care system. Limited pediatric
142 seroprevalence data exist for SARS-CoV-2. Following the first pandemic wave in Spain, up to a 6.2%
143 seropositivity was reported late April/early May 2020, with only 3.8% of children aged 0-19 years being
144 seropositive [3]. Antibody positivity in a smaller population-based study in Switzerland in mid-May 2020
145 was lowest in children 0-9 years at 0.8%, compared with adults aged 20-49, at 9.9% [4]. Similarly, in
146 Germany a low seropositivity rate of 0.6% was reported in children aged 1-10 years [5],

147 An investigation in spring 2020 evaluated children for SARS-CoV-2 antibodies 8-10 weeks after a large
148 school outbreak in Santiago, Chile. Anti-SARS-CoV-2 antibodies were present in 10% of children,
149 whereas 17% of adult staff were seropositive. Forty percent of seropositive children were categorized as
150 asymptomatic [6]. Outside of this outbreak associated investigation, there have been no large pediatric
151 focused seroprevalence studies in the Americas.

152 Compared to adults, preliminary evidence in children suggests a distinct antibody response to SARS-
153 CoV-2 infection, with a reduced breadth of anti-SARS-CoV-2 antibodies, specifically a reduction in anti-
154 nucleocapsid antibody production [7]. Furthermore, the possibility has been raised that children may have

155 a higher prevalence of antibodies against the S2 unit of the SARS-CoV-2 spike protein, which may be
156 partially due to cross-reactivity to conserved epitopes in benign seasonal human coronaviruses [8].

157 As there is extremely limited data regarding the burden of SARS-CoV-2 infection in children, especially
158 in the US, the primary objective of this study was to determine SARS-CoV-2 seroprevalence in children
159 residing in Northern Virginia in the US. Northern Virginia is the most populous and urbanized region of
160 Virginia and is geographically linked to the Washington, D.C. metropolitan area. Secondary objectives
161 included identification of risk factors associated with SARS-CoV-2 seropositivity in children, orthogonal
162 antibody testing to assess the accuracy of antibody testing in children and evaluation of immunologic
163 responses to different antigens of SARS-CoV-2 in children.

164

165 **Methods**

166 Children and adolescents were enrolled in this cross-sectional, observational study over a 10-week period,
167 from July 31 to October 13, 2020. Verbal informed consent was obtained from parents and adolescents
168 ≥ 18 years. The Inova Health Systems Human Research Protection Office waived ethics approval as per
169 CFR 45 46.102, as this project was a public health surveillance activity, funded by the Virginia
170 Department of Health (VDH). During the study period, public schools in Northern Virginia were closed
171 to in-person learning although, some childcare facilities remained open. An indoor mask mandate outside
172 the home was in effect; however, this was only for children ≥ 10 years and adults.

173 Subjects were recruited from three settings in Northern Virginia: 1) non-emergency health care settings
174 (including pediatric primary care offices, pediatric specialty clinics and pre-surgical areas for elective
175 procedures); 2) self-referral in response to advertisement of the study, and 3) the Inova Children's
176 Hospital Pediatric Emergency Department and limited enrollment from inpatient units. Inclusion criteria
177 were ≤ 19 years (the age range defined as a child for COVID-19 reporting by the state of Virginia) and
178 residence in Virginia. Only one individual per household was permitted to enroll in the study. Exclusion

179 criteria included receipt of immunoglobulin therapy within the past 11 months, including intravenous
180 immunoglobulin, whole blood, fresh frozen plasma, experimental therapy with convalescent plasma, or
181 other blood product transfusions, except for packed red blood cells and platelets.

182 Enrolled participants completed a questionnaire collecting demographic, health and potential COVID-19
183 exposure information. Blood was collected by venipuncture, either for the sole purpose of the study or in
184 conjunction with another clinical blood draw. Blood was tested using the US Food and Drug
185 Administration emergency use authorized Ortho Clinical Diagnostics VITROS Immunodiagnostic
186 Products Anti-SARS-CoV-2 Total test (Ortho Clinical) performed on the Vitros 3600 system (Ortho
187 Clinical Diagnostics, Raritan, NJ) to detect total antibody (IgG, IgA and IgM) responses against the
188 SARS-CoV-2 spike protein. This assay has a reported clinical specificity of 100% (95% CI: 99.1-100%)
189 [9]. Samples were documented as reactive (≥ 1.00 S/Co) or non-reactive (< 1.00 S/Co) for anti-SARS-
190 CoV-2.

191 Orthogonal antibody testing was performed on reactive samples as the estimated prevalence prior to the
192 study was 1%, based on very limited data at the time.⁴ Orthogonal serologic testing was recommended by
193 the CDC for populations with a low pre-test probability, including low or unknown prevalence of disease
194 [10]. In such conditions, an initial antibody assay is performed, and then on all positive tests, a secondary
195 assay with a different or more focused target is performed. In this study, the Ortho Clinical assay
196 (targeting the total protein - S1 and S2 subunits) was used as the primary assay, followed by the Siemens
197 SARS-CoV-2 IgG assay solely targeting the S1 unit receptor binding domain (RBD) (Siemens
198 Healthineers, Erlangen, Germany). Additionally, to assess the antibody response in children to different
199 SARS-CoV-2 antigens, all initially reactive samples were tested using the Abbot nucleocapsid IgG
200 antibody assay (Abbott Laboratories, Chicago, IL). Furthermore, a random 10% sample of the initial
201 non-reactive samples on the Ortho Clinical assay were analyzed on the Siemens (RBD) and Abbot
202 (nucleocapsid) IgG assays.

203 Sample size justification was based on early estimates suggesting a SARS-CoV-2 seroprevalence in
204 children of approximately 1% [4]. Thus, in order to estimate the seropositivity in demographic subgroups
205 while considering the clustering effect due to testing at different enrollment sites, 80% Wilson score
206 intervals were used to determine a total sample size of at least 1,000 children.

207 Statistical analysis methods included both comprehensive descriptive statistics and statistical modeling.
208 Positive frequency counts were used to estimate both the overall and subgroup prevalence rates to
209 delineate the effects of different factors. The corresponding Wilson score intervals provided the
210 uncertainty quantification of the prevalence estimates. Graphical diagnostics and chi-squared tests of
211 independence were used to determine whether selected covariates were correlated. Univariate and
212 multivariate logistic regression analyses of antibody presence were used to explore potential effects from
213 covariates. A final logistic regression model was chosen using a stepwise model selection. Odds ratios
214 with corresponding confidence intervals were calculated for the coefficients in the model. The
215 distribution of antibody titer levels across different factor levels was examined. Kruskal-Wallis tests were
216 used to determine if these distributions differed across potential risk factors. Simple inter-rater reliability
217 rates were calculated to assess orthogonal testing results. R version 4.0.3 was used to perform statistical
218 analyses.

219 **Results**

220 This study included 1038 children. Demographic and clinical data are shown in Table 1. All age groups
221 between 0–19 years were well represented, and racial and ethnic diversity was reflective of the Northern
222 Virginia populace.

223 Table 1 shows the prevalence rates for anti-SARS-CoV-2 total antibody (Ortho Clinical assay) across
224 demographic and clinical covariates of interest. The overall positivity rate for anti-SARS-CoV-2 total
225 antibody was 8.5% (88/1038). SARS-CoV-2 antibodies were found in 8.2% of White children, 5.2% of
226 Black or African American children, 5.7% of Asian children, and 16.2% of children identified as other

227 racial origin. When compared by age groups a bimodal distribution was noted with a seropositive rate of
228 13.7% in young children 0–5 years, 7.5% in school-age children 6–10 years, 5.1% in early adolescents
229 11–15 years and 10.8% in older adolescents 16–19 years (Supplemental Figure 1).

230 Especially high prevalence rates were noted in children with Hispanic ethnicity (26.8%, 55/207), those
231 with public insurance (Medicaid, 21.6% 27/125), those without insurance (55.0%, 11/20), children living
232 in multi-family or apartment dwellings without a private entrance (28.7%, 33/115), and children recruited
233 from safety net primary care clinic (primary care location 2, 25%, 16/64) (Figure 1).

234 Of children exposed to an individual with a known history of COVID-19, 33.0% (35/106) had antibodies.
235 Living in the same household with a person who tested positive for SARS-CoV-2 increased the
236 seroprevalence rate to 52.5% (31/59). Having a personal history of symptoms consistent with COVID-19
237 was associated with a seroprevalence of 11.8% (30/255). However, 65.9% (58/88) of children with
238 positive antibody testing had no personal history of symptoms, and 54.6% (48/88) had no known
239 exposure.

240 After multiple regression, significant factors associated with seropositivity were found to include
241 ethnicity, age group, insurance status, symptoms consistent with COVID-19, having a household member
242 test positive for COVID-19 and dwelling type (Table 2).

243 A final multivariate logistic regression model was chosen using stepwise model selection. Remaining
244 significant predictors included Hispanic ethnicity, lack of insurance or public insurance, a history of
245 symptoms suggestive of COVID-19, exposure to an individual with a history of COVID-19, a household
246 member testing positive for COVID-19, and living in a multi-family or apartment dwelling without
247 private entrance (Table 3).

248 Of those who tested positive for anti-SARS-CoV-2, titer levels ranged from 1.05 to 1000 S/Co. Across
249 all age groups, titer levels did not significantly differ (Kruskal-Wallis, $p=0.088$) (Supplemental Figure 2).

250 There was no significant difference in titer levels between those with no symptoms, those with symptoms

251 within 2 weeks of testing, and those with symptoms more than 2 weeks before testing (p -value=0.893,
252 Kruskal-Wallis) (Supplemental Figure 3).

253 Orthogonal testing was performed on 87/88 reactive samples (where enough serum remained) using the
254 Siemens assay against the S1/RBD target. This demonstrated an 80.5% agreement with 70/87 samples
255 reactive. Those with lower titer levels on the Ortho Clinical assay were more likely to test negative on the
256 Siemens assay (p =0.001, logistic regression) and older individuals were more likely to test negative
257 (p =0.011, logistic regression); Figure 2a. There was no significant difference between those with recent
258 symptoms within 2 weeks versus those with more remote symptoms in negative results on orthogonal
259 testing.

260 When comparing reactive samples from the Ortho Clinical assay with the Abbot assay targeting the
261 nucleocapsid antigen there was a 79.3% agreement with 69/87 samples testing positive. Those in older
262 age groups were more likely to test negative on the Abbot assay (p =0.001, logistic regression) but there
263 was no significant change among titer levels (p =0.177, logistic regression); Figure 2b.

264 A random selection of 98 samples (approximately 10%) that tested non-reactive on the Ortho Clinical
265 assay were tested on both the Abbot and Siemens assays. All samples were negative on the additional two
266 assays.

267 **Discussion**

268 Using the Ortho Clinical anti-SARS-CoV-2 antibody assay, it was determined that the seroprevalence of
269 SARS-CoV-2 in children in Northern Virginia was as high as 8.5% (95% CI 6.9-10.3) in the fall of 2020.
270 In contrast, the concurrently reported prevalence of SARS-CoV-2 in children in Virginia and throughout
271 the US, based on molecular and antigen tests at the time of study completion, was around 1% [11]. Our
272 seropositive rate of infection in children was almost 8 times the reported prevalence based on real-time
273 viral testing.

274 An independently determined Northern Virginia adult seroprevalence was 4.4% in a similar study that
275 concluded 2 months prior to this pediatric study (personal communication, author Christopher Difillipi).
276 As of mid-October, the Centers for Disease Control reported a Virginia adult seroprevalence of 4.1%
277 [12]. The seropositivity rate in children in this current study was more than double the reported
278 concurrent adult seroprevalence.

279 The higher than expected pediatric seropositivity rate in our study is in part likely attributable to
280 continued viral transmission over time. In addition, early in the pandemic, it was perceived that children
281 were at reduced risk for acquiring COVID-19, either from innate protective physiologic characteristics or
282 reduced exposure [1,3]. Schools closed rapidly at the start of the pandemic with reduced communal
283 exposure. However, the unrecognized burden of mild or asymptomatic disease, resulted in testing bias
284 and under-representation of children in early testing schemes [1, 13-15]. The high SARS-CoV-2
285 seropositivity in children we identified was an unexpected finding and it has important implications for
286 this silent burden of disease and risk of transmission to and from children.

287 In our population, after multi-regression analysis, identified significant risk factors for seropositivity
288 included: age-group, Hispanic ethnicity, insurance status, and residence within a multi-family dwelling or
289 apartment without a private entrance. The highest risk belonged to children living in the same home as an
290 individual who had tested positive for SARS-CoV-2, with an odds ratio of 22.

291 Children under 5 years were statistically more likely to be seropositive for SARS-CoV-2 compared with
292 other age groups in univariate analysis. This finding was also surprising and has implications for the need
293 for different considerations in mitigation and protection strategies in the younger age groups. Neither the
294 Spanish nor Switzerland cohorts examined children <5 years, but adolescents (ages 10-19) in Switzerland
295 were more likely to test positive for antibodies than younger children (ages 5-9) [3,4]. Young children are
296 cared for more closely by adults with possible higher risk of exposure due to prolonged physical
297 proximity and are more likely to interact with each other with less protection. Additionally, even though
298 there was an indoor mask mandate outside the home, this was only for children ≥ 10 years. Moreover,

299 even as public schools were closed for in-person learning, some childcare facilities for younger children
300 remained open. However, consistent with other reports, our analyses did not indicate a significant
301 difference in seropositivity in children cared for outside of their home, probably because greater efforts
302 are taken to prevent transmission in childcare settings [16].

303 The majority of children with anti-SARS-CoV-2 antibodies in this cohort (66%) did not recall having
304 symptoms of COVID-19. While the veracity of this is affected by recall bias, this highlights the high
305 proportion of infections that are asymptomatic in the pediatric population and the subsequent risk of
306 transmission to other vulnerable persons.

307 For seropositive individuals, mean antibody titers did not appear to differ between those with or without
308 symptoms, recent or remote. It is interesting that for some seropositive children, symptoms were reported
309 <2 weeks from testing as the reported kinetics of the antibody response to SARS-CoV-2 demonstrate that
310 at least a week is necessary to mount IgM responses after onset of symptomatic disease [15]. Since
311 COVID-19 symptoms overlap greatly with other childhood viral syndromes, it is possible that these
312 reported symptoms were not truly caused by COVID-19 infection. It is also possible that some children
313 with remote symptomatology had seroreversion and so were not captured in the positive cohort [17,18].

314 Exposure to infectious persons with COVID-19 is a well-recognized risk factor for acquiring COVID-19
315 and our analysis confirms this [19-22]. Consistent with other reports, the household attack rate was even
316 higher; over 50% of children reported as exposed to a test-positive household member were seropositive
317 [23]. Conversely, almost 60% of seropositive children had no known contact with test-positive SARS-
318 CoV-2. This emphasizes the insidious effects of asymptomatic spread with viral shedding in symptomatic
319 and asymptomatic individuals [24].

320 Ethnically and socioeconomically marginalized groups unable to shelter in place have shouldered a
321 disproportionate burden of COVID-19 disease globally [23,26,27]. Hispanic ethnicity, the dominant
322 minority in Northern Virginia, conferred four-fold odds of seropositivity. Publicly provided health

323 insurance and lack of insurance is an accepted marker for lower socioeconomic status, and families with
324 limited financial means are more likely to live in multi-family dwellings with a common entrance.
325 Significantly higher seropositivity rates in each of these groups demonstrated the disproportionate impact
326 of COVID-19 on the underprivileged.

327 Orthogonal testing with an antibody assay specific to the S1/RBD antigen of the spike protein
328 demonstrated high concordance. Those samples which failed to show concordance in orthogonal testing
329 to the S1/RBD exhibited very low titers to the full spike protein (Ortho Clinical assay). Future
330 consideration should be given to redefining the lower limit of detection for full spike protein antibody
331 assays as it is possible that these lower titer levels may represent cross-reactivity to conserved epitopes in
332 benign seasonal human coronaviruses [8]. In addition, some samples that may have been negative on
333 orthogonal testing may have been due to the Ortho Clinical assay also detecting IgM; however those
334 negative on orthogonal testing were not more likely to have recent symptoms consistent with COVID-19
335 within 2 weeks of antibody testing.

336 Children with a response to the full spike protein assay also frequently manifested antibodies to the
337 nucleocapsid antigen. Interestingly, it was those in older age groups that more likely failed to produce a
338 nucleocapsid antibody response, contrary to previously published data suggesting that young children
339 may fail to elicit a nucleocapsid antibody response [7].

340 **Limitations**

341 There are several potential limitations to this investigation. Selection bias may have affected the
342 representativeness of the regional population, as it was focused on children having blood drawn for
343 another clinical purpose and self-referral for the study. However, these factors are accounted for in this
344 analysis. In addition, Northern Virginia is a major metropolitan area, and so results may not be
345 generalizable to areas that have more rural demographics. As noted, cross-reaction with other common
346 endemic human beta-coronaviruses may result in false positive antibody results, particularly at currently

347 defined thresholds [8]. Conversely, seroreversion may produce false negative results in more remote
348 infections [23,24]. Most importantly, this study took place at a specific point in time and represents a
349 static snapshot of a dynamic event [4].

350 **Conclusions**

351 A much higher pediatric SARS-CoV-2 burden was found than has previously been reported in the US;
352 this rate was also higher than in adults in the same region over a similar time period. These seropositive
353 rates were following the period after the first peak of infection in the community, when schools were
354 closed, and social mitigation strategies were mandated. Contrary to reporting early in the COVID-19
355 pandemic, this study determined that children experience a significant burden of COVID-19 infection.
356 Children appear very important in the transmission of disease, including silent transmission, and with
357 such continued protection of children through social mitigation strategies and extending COVID-19
358 vaccines to children are imperative to achieving control of this pandemic.

359

360

361

362

363

364

365

366

367

368

369

370

371 **Acknowledgements**

372 We recognize the efforts of all team members at the multiple study sites who have supported this
373 study and encouraged participation. This project would not have been possible without the
374 support of Dr. David Trump and the Virginia Department of Health, the help of Dr. John Farrell
375 and Dr. Dina Gottsman and the pediatric team at Farrell Pediatrics, Dr. Albert Brito and the
376 pediatric team at Inova Cares Clinic for Children, Dr. Sandy Chung and the pediatric team at
377 Fairfax Pediatrics, and Dr. Christina Ulen, Ms. Lori Schubert, and the pediatric team at
378 Advanced Pediatrics, Dr. Elizabeth Yang and the pediatric teams at Pediatric Specialists of
379 Virginia, the pediatric teams at Inova Children’s Hospital. We recognize and thank all of the
380 participants of the study and their families; such studies can only happen because people find
381 that helping in research, especially in the midst of a pandemic, is worthwhile, and therefore,
382 choose to join.

References

1. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(14):422-426.
2. Pan Y, Li X, Yang G, et al. Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign. *Clin Microbiol Infect.* Published online October 6, 2020. doi:10.1016/j.cmi.2020.09.044
3. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet.* 2020;396(10250):535-544.
4. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet.* 2020;396(10247):313-319.
5. Tönshoff B, Müller B, Elling R, et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. *JAMA Pediatr.* Published online January 22, 2021. doi:10.1001/jamapediatrics.2021.0001
6. Torres JP, Piñera C, De La Maza V, et al. SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study. *Clin Infect Dis.* Published online July 10, 2020. doi:10.1093/cid/ciaa955
7. Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat Immunol.* 2021;22(1):25-31.
8. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science.* 2020;370(6522):1339-1343.
9. <https://www.fda.gov/media/136967/download> (Accessed January 14, 2021)
10. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html>. (Accessed December 30,2020)
11. <https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/> (accessed Nov 8, 2020)
12. https://covid.cdc.gov/covid-data-tracker/#trends_totalandratercases (Accessed Nov 8,2020)
13. DeBiasi RL, Delaney M. Symptomatic and Asymptomatic Viral Shedding in Pediatric Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Under the Surface. *JAMA Pediatr.* Published online August 28, 2020. doi:10.1001/jamapediatrics.2020.3996
14. Han MS, Choi EH, Chang SH, et al. Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. *JAMA Pediatr.* Published online August 28, 2020. doi:10.1001/jamapediatrics.2020.3988

15. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*. 2020;323(22):2249-2251.
16. Link-Gelles R, DellaGrotta AL, Molina C, et al. Limited Secondary Transmission of SARS-CoV-2 in Child Care Programs - Rhode Island, June 1-July 31, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(34):1170-1172.
17. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. *Pediatr Infect Dis J*. 2020;39(5):355-368.
18. Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(47):1762-1766.
19. Hobbs CV, Martin LM, Kim SS, et al. Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged <18 Years - Mississippi, September-November 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(50):1925-1929.
20. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2020;3(12):e2031756.
21. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 Infections in Households - Tennessee and Wisconsin, April-September 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(44):1631-1634.
22. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med*. 2020;383(18):1724-1734.
23. Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. *JAMA Pediatr*. Published online November 23, 2020. doi:10.1001/jamapediatrics.2020.5052
24. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe*. Published online November 19, 2020. doi:10.1016/S2666-5247(20)30172-5
25. Leeb RT, Price S, Sliwa S, et al. COVID-19 Trends Among School-Aged Children - United States, March 1-September 19, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(39):1410-1415.
26. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. *JAMA*. 2020;324(3):259-269.
27. DeBiasi RL, Song X, Delaney M, et al. Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. *J Pediatr*. 2020;223:199-203.e1.

Figure Legends:

Figure 1: Wilson Score intervals for selected covariates of interest.

Figure 2. Scatterplots showing age versus titer levels of the reactive tests on the Ortho Clinical Diagnostic Vitros assay, with orthogonal testing on the Siemens assay (2a) and Abbot assay (2b). Negative tests on orthogonal testing are colored red.

Supplemental Figure 1: Pairwise plot of age vs. seropositivity rate (%). The red points represent the observed positivity rate in the cohort at each age, and the line is the predicted positivity rate produced by a quadratic regression model. The estimated seropositivity rate is higher for younger and older ages of children.

Supplemental figure 2: A multiple boxplot that shows the SARS-CoV-2 total spike protein titer levels (S/Co) for those who tested positive separated by age group and summary statistics.

Supplemental Figure 3: A multiple boxplot that showing SARS-CoV-2 total spike protein titer levels (S/Co) for those who tested positive separated by presence of symptoms and summary statistics.

Table 1: Demographic Information, Prevalence Rates, and 95% Wilson Score Intervals					
*Indicates an unreliable estimate due to a small count					
Variable	Category	Count	Estimated Prevalence Rate	95% Wilson Score Intervals	
				Lower Bound	Upper Bound
Overall		1038	8.5%	6.9%	10.3%
Gender	Male	499	8.4%	6.3%	11.2%
	Female	536	8.6%	6.5%	11.3%
	Not Disclosed	3	0%*	0%	56.1%
Age Group	0 – 5 years	182	13.7%	9.5%	19.5%
	6 – 10 years	241	7.5%	4.8%	11.5%
	11 – 15 years	374	5.1%	3.3%	7.8%
	16 – 19 years	241	10.8%	7.5%	15.3%
Race	White	717	8.2%	6.4%	10.5%
	Black or African American	97	5.2%	2.2%	11.5%
	Asian	106	5.7%	2.6%	11.8%
	American Indian or Alaska Native	0	---	---	---
	Native Hawaiian or Other Pacific Islander	2	0%*	0%	65.8%
	Other	111	16.2%	10.5%	24.2%
	Unknown/Declined	5	0%*	0%	43.4%
Ethnicity	Not Hispanic or Latino	829	4.0%	2.8%	5.5%
	Hispanic or Latino	207	26.6%	21.0%	33.0%
	Unknown	2	0%*	0%	65.8%
Insurance	Private	834	5.3%	4.0%	7.0%
	Medicaid	125	21.6%	15.3%	29.6%
	Medicare	8	12.5%*	2.2%	47.1%
	None or uninsured	20	55.0%	34.2%	74.2%
	Other	3	33.3%*	6.1%	79.2%
	Don't know	4	25.0%*	4.6%	69.9%
	Military	44	6.8%	2.3%	18.2%
Existing Medical Comorbidity	No	807	8.3%	6.6%	10.4%
	Yes	225	8.9%	5.8%	13.3%
	Don't Know	3	0%*	0%	56.1%
	Missing	3	33.3%	---	---
Symptoms	No	774	7.2%	5.6%	9.3%
	Yes	255	11.8%	0%	65.8%
	Unknown	6	33.3%*	9.7%	70.0%

	Missing	3	0%	---	---
Dwelling	Single-family	901	5.9%	4.5%	7.6%
	Multi-family or apartment – No Private Entrance	115	28.7%	21.2%	37.5%
	Multi-family or apartment – Private Entrance	16	6.3%	1.1%	28.3%
	Other	6	16.7%*	3.0%	56.4%
Household Member Exposure	Not Tested	543	6.3%	4.5%	8.6%
	Tested – Positive	59	52.5%	40.0%	64.7%
	Tested – Negative	415	5.3%	3.5%	7.9%
	Tested – No Results	15	6.67%	1.19%	29.8%
	Unknown if Tested	4	0%*	0%	49.0%
	Missing	2	0%	---	---
COVID-19 Exposure	No	911	5.6%	4.3%	7.3%
	Yes	106	33.0%	24.8%	42.4%
	Unknown or Missing	19	10.5%	2.9%	31.4%
	Missing	2	0%	---	---
Reason for Visit	Specifically for COVID-19 antibody testing	504	4.6%	3.1%	6.8%
	New or acute illness or injury	193	14.0%	9.8%	19.6%
	Prevention or well visit	59	20.3%	12.0%	32.3%
	Routine visit for a prior condition	193	8.8%	5.6%	13.7%
	Other	84	10.1%	5.4%	18.1%
Traveled Out of the State	No	395	13.4%	10.4%	17.1%
	Yes	642	5.5%	3.9%	7.5%
	Don't Know	1	0%*	0%	79.3%
Traveled Out of the Country	No	1002	8.4%	6.8%	10.3%
	Yes	36	11.1%	4.4%	25.3%
Child Cared for outside of Home	No	729	8.2%	6.4%	10.5%
	Yes	299	8.7%	6.0%	12.4%
	Missing	10	20.0%	---	---
Household Member Work Outside the Home	No work outside home	383	6.3%	4.2%	9.2%
	Essential	530	8.7%	6.6%	11.4%
	Unessential	121	14.0%	9.0%	21.4%
	Unknown if essential	3	33.3%*	6.1%	79.2%
	Missing	1	0%	---	---
Enrollment Site	Pediatric Specialists Clinics	444	4.7%	3.1%	7.1%
	Pediatric Emergency Department	175	14.3%	9.9%	20.2%
	Pre surgical areas	89	6.7%	3.1%	13.9%
	Primary Care location 1	128	5.5%	2.7%	10.9%
	Hematology/Oncology clinic	57	17.5%	9.8%	29.4%
	Primary Care location 2	64	25.0%	16.0%	36.8%
	Pediatric Intensive Care Unit	7	14.3%*	2.6%	51.3%
	Pediatric inpatient units	6	0%*	0%	39.0%
	Endoscopy suite	10	0%*	0%	27.8%
	Primary Care location 3	49	4.1%	1.1%	13.7%

	All other Primary Care clinics	9	0%*	0%	29.9%
--	--------------------------------	---	-----	----	-------

Covariate	Covariate p-value		Level	Level p-value	
	Univariate	Multivariate		Univariate	Multivariate
Gender	0.763	0.749	Male	Baseline	
			Female	0.924	0.998
			Not Disclosed	0.981	0.996
Age Group	0.003	0.009	0 – 5 years	< 0.001	0.534
			6 – 10 years	0.227	0.857
			11 – 15 years	Baseline	
			16 – 19 years	0.009	0.534
Race	0.051	0.143	White	Baseline	
			Black or African American	0.296	0.202
			Asian	0.363	0.701
			Native Hawaiian or Other Pacific Islander	0.990	0.997
			Other	0.008	0.129
			Unknown/Declined	0.984	0.996
Ethnicity	< 0.001	< 0.001	Not Hispanic or Latino	Baseline	
			Hispanic or Latino	< 0.001	0.001
			Unknown	0.985	0.998
Insurance	< 0.001	0.002	Private	Baseline	
			Medicaid	< 0.001	0.065
			Medicare	0.383	0.448
			None or uninsured	< 0.001	< 0.001
			Other	0.075	0.126
			Don't know	0.125	0.802
			Military	0.659	0.046
Existing Medical Comorbidities	0.739	0.554	No	Baseline	
			Yes	0.780	0.518
			Don't know	0.981	0.996
Symptoms	0.021	0.033	No	Baseline	
			Yes	0.025	0.025
			Unknown	0.034	0.464
Dwelling	< 0.001	0.005	Single-family	Baseline	
			Multi-family or apartment – no private entrance	< 0.001	0.006
			Multi-family or apartment– private	0.951	0.734

			entrance		
			Other	0.292	0.554
Household Member Tested for COVID-19	< 0.001	< 0.001	Not Tested	Baseline	
			Tested – Positive	< 0.001	< 0.001
			Tested – Negative	0.531	0.097
			Tested – No Results	0.949	0.655
			Unknown if Tested	0.986	0.997
Child Exposed to COVID-19	< 0.001	0.056	No	Baseline	
			Yes	< 0.001	0.114
			Unknown	0.368	0.066
Traveled Out of State	< 0.001	0.218	No	Baseline	
			Yes	< 0.001	0.114
			Unknown	0.983	0.998
Traveled Out of Country	0.580	0.234	No	Baseline	
			Yes	0.565	0.076
Reason for Visit	< 0.001	0.243	Specifically for COVID antibody testing	Baseline	
			New or acute illness or injury	< 0.001	0.287
			Prevention or well visit	< 0.001	0.422
			Routine visit for a prior condition	0.034	0.343
			Other	0.038	0.596
Work Out of Home	0.041	0.222	None	Baseline	
			Essential	0.178	0.424
			Unessential	0.008	0.173
			Yes, Not Sure if Essential	0.105	0.657
Childcare out of Home	0.807	0.056	No	Baseline	
			Yes	0.807	0.052
Household Size	0.239	0.439	---	0.230	0.283
Children in Household	0.145	0.013	---	0.154	0.014
Enrollment Site	< 0.001	0.883	Pediatric Emergency Department	Baseline	
			Pre surgical areas	0.079	0.539
			Primary Care location 1	0.017	0.899
			Pediatric Specialists Clinics	< 0.001	0.879
			Hematology/Oncology clinic	0.551	0.378


			Primary Care location 2	0.055	0.543
			Pediatric Intensive Care Unit	1.000	0.778
			Pediatric inpatient units	0.988	0.995
			Endoscopy suite	0.985	0.993
			Primary Care location 3	0.070	0.726
			All other Primary Care clinics	0.985	0.995

Table 3: Odds Ratio Estimates and p-values for Chosen Covariates


Covariate	Level	Univariate Analysis		Multivariate Analysis	
		OR (95% CI)	p-value	OR (95% CI)	p-value
Ethnicity	Not Hispanic or Latino	Baseline		Baseline	
	Hispanic or Latino	8.73 (5.51, 14.02)	< 0.001	4.22 (2.26, 7.94)	< 0.001
	Unknown	---	0.985	---	0.994
Insurance	Private	Baseline		Baseline	
	Medicaid	4.95 (2.91, 8.31)	< 0.001	2.45 (1.10, 5.39)	0.027
	Medicare	2.56 (0.14, 14.86)	0.383	0.47 (0.01, 7.05)	0.628
	None or uninsured	21.94 (8.65, 57.16)	< 0.001	11.95 (3.71, 38.43)	< 0.001
	Other	8.98 (0.41, 95.46)	0.075	5.11 (0.22, 60.29)	0.206
	Don't know	5.98 (0.29, 47.83)	0.125	1.93 (0.08, 19.29)	0.603
	Military	1.31 (0.31, 3.80)	0.659	3.37 (0.73, 11.40)	0.075
Symptoms	No	Baseline		Baseline	
	Yes	1.71 (1.06, 2.71)	0.025	1.99 (1.05, 3.72)	0.033
	Unknown	6.41 (0.88, 33.59)	0.034	4.36 (0.27, 53.50)	0.292
Dwelling	Single-family	Baseline		Baseline	
	Multi-family – no private entrance	6.44 (3.92, 10.48)	< 0.001	3.19 (1.57, 6.43)	0.001
	Multi-family – private entrance	1.07 (0.06, 5.42)	0.951	0.71 (0.04, 4.63)	0.765
	Other	3.20 (0.17, 20.31)	0.292	1.15 (0.03, 17.95)	0.931
Household Member COVID-19 Test Results	Not Tested	Baseline		Baseline	
	Tested – Positive	16.57 (8.98, 31.02)	< 0.001	9.65 (3.34, 30.55)	< 0.001
	Tested – Negative	0.84 (0.48, 1.45)	0.531	0.69 (0.35, 1.33)	0.281
	Tested – No Results	1.07 (0.06, 5.57)	0.949	2.36 (0.12, 15.00)	0.446
	Unknown if Tested	---	0.986	---	0.993
Child Exposed to COVID-19	No	Baseline		Baseline	
	Yes	8.31 (5.06, 13.60)	< 0.001	2.93 (1.06, 7.45)	0.030

	Unknown	1.98 (0.31, 7.18)	0.368	3.22 (0.46, 13.79)	0.160
Travel Out of State	No	Baseline		Baseline	
	Yes	0.37 (0.24, 0.58)	< 0.001	0.53 (0.28, 0.98)	0.045
	Unknown	---	0.983	---	0.995
Number of Children		0.84 (0.66, 1.06)	0.154	0.67 (0.48, 0.92)	0.016

Wilson Score Intervals for Selected Categories



**Siemens Test Results Among
Positive Ortho Tests**



**Abbot Architect Results Among
Positive Ortho Tests**

